|
IQVIA™ Real-World Insights Bibliography
| Cost-Effectiveness of Switching to Biphasic Insulin Aspart in Poorly-Controlled Type 2 Diabetes Patients in China |
| Author(s): Palmer JL1, Gibbs M2, Scheijbeler H3, Kotchie R3, Nielsen S4, White J5, Valentine WJ1 |
| Affiliations(s): 1IMS Health, Basel, Switzerland, 2IMS Health, Shanghai, China, 3IMS Health, London, UK, 4Novo Nordisk A/S, Bagsværd, Denmark, 5Novo Nordisk International Operations A/S, Zurich, Switzerland |
Publication(s): Adv Ther. 2008 Aug;25(8):752-74.
|
| Document Type(s): Article, |
| Countries: China, |
C:
Y: |
Diabetes,
2008 |
|
L:
A: |
English
Cost effectiveness, |
|
 |
| |
| |
| Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analyses in a Chinese setting. |
| Author(s): Chen X1, Clegg JP2, Chen L1, Yu H3, Wittrup-Jensen KU4, Valentine WJ1 |
| Affiliations(s): 1Fu Dan University, Shanghai, China, 2IMS Health, Basel, Switzerland, 3Bayer Healthcare Co. Ltd, Shanghai, China, 4Bayer Schering Pharma AG, Berlin, Germany |
Publication(s): 3rd Asia-Pacific Conference, 7-9 September 2008
|
| Document Type(s): Oral presentation, |
| Countries: China, |
| Click here for the abstract |
C:
Y: |
Diabetes,
2008 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Cost-effectiveness of biphasic insulin aspart 30 versus human premix insulin for type 2 diabetes patients in China |
| Author(s): Lynch M1, Scheijbeler HW2, Kotchie R2, Valentine WJ3, Nielsen S4, White J5 |
| Affiliations(s): 1IMS Health, Shanghai, China; 2IMS Health, London, UK; 3 IMS Health, Basel, Switzerland; 4Novo Nordisk, Bagsværd, Denmark; 5Novo Nordisk, Zürich, Switzerland |
Publication(s): ISPOR 2007 10th Annual European Congress, Athens, Greece, 8 ? 11 November 2008
|
| Document Type(s): Poster, |
| Countries: China, |
C:
Y: |
Diabetes,
2007 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Asthma control and its direct healthcare costs: findings using a derived Asthma Control Test (ACT) score in eight Asia-Pacific areas. |
| Author(s): Lai CKW1 Kuo S-H2 de Guia T3 Lloyd A4, Williams AE5, Spencer MD5 |
| Affiliations(s): 1 Dept of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong 2 National Taiwan University Hospital, Taipei, Taiwan 3 Philippine Heart Centre, Quezon City, The Philippines 4 Fourth Hurdle Consulting Ltd, London, UK 5 GlaxoSmithKine R&D, Greenford, UK |
Publication(s): European Respiratory Review 2006; 15:(98): 24-29
|
| Document Type(s): Manuscript in preparation, |
| Countries: China, Hong Kong, Malaysia, Philippines, Singapore, Taiwan, Vietnam, |
C:
Y: |
Respiratory disease,
2006 |
|
L:
A: |
English
Cost of illness, |
|
|
| |
| |
| Potential savings with everolimus with reduced-dose cyclosporine compared to mycophenolate motefil with full dose cyclosporine in de novo renal transplant recipients in China. |
| Author(s): Yang X, Ethgen O, Wang W, Lian R, Ricci JF, Spaepen E et al. |
| Affiliations(s): |
Publication(s): ISPOR 2nd Asia-Pacific Congress, Shanghai, China
|
| Document Type(s): Poster, |
| Countries: China, |
C:
Y: |
Nephrology,
2006 |
|
L:
A: |
English
|
|
|
| |
| |
 4 of 4
|
|
